BIOSCEPTRE Takes Centre Stage At Cell & Gene Therapy World Asia Congress 2026
We are proud to have shared the platform twice this [...]
BIOSCEPTRE to present at ANZ BIOLOGICS FESTIVAL 2026
We are pleased to be showcasing the progress of the [...]
Biosceptre Secures £8.1 Million to Accelerate Innovative Cancer Therapies
Cambridge, UK – 1 October 2025 – Biosceptre International Limited [...]
Closing Date Extension for £10 Million Placement to Eligible Existing Shareholders
6 August 2025 – Biosceptre International Limited ("Biosceptre" or "the [...]
Biosceptre Announces £10 Million Placement to Eligible Existing Shareholders
24 June 2025 – Biosceptre International Limited ("Biosceptre" or "the [...]
Biosceptre presenting our AML Modular CAR-T program at the prestigious European Hematological Congress
Biosceptre is proud to announce that lead scientists Alex Joechner [...]
Biosceptre’s BRiDGECAR™ Platform Recognised at Two Major Global Conferences!
We’re excited to announce that our BRiDGECAR™ T-cell platform [...]
Professor Shane Grey Appointed Chairman of Biosceptre’s Scientific Advisory Board
Biosceptre is proud to announce that Professor Shane Grey has [...]
Antibody and CAR-T optimisation work continues with collaboration with Garvan and support of NHMRC Grant
Biosceptre’s collaboration with Garvan on antibody development and optimisation continues [...]
Professor Shane Grey Joins the Biosceptre Scientific Advisory Board
We are pleased to announce the appointment of Professor Shane [...]